<DOC>
	<DOCNO>NCT00003048</DOCNO>
	<brief_summary>RATIONALE : Amifostine may improve blood count patient myelodysplastic syndrome . PURPOSE : Phase II trial study effectiveness amifostine treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Amifostine Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Define activity amifostine improve blood count patient myelodysplastic syndrome . OUTLINE : This open label , nonrandomized , single center , dose escalation study . Patients receive amifostine IV two week , follow 2 week rest . Each treatment cycle 4 week . Responses evaluate cycle ( minimum 2 induction cycle ) . Patients grade 0 toxicity first course receive 25 % increase dose second course . Patients grade 1 2 toxicity receive dose change . Patients grade 3 toxicity receive 25 % reduction dose treatment stop . All patient demonstrate response eligible maintenance therapy . Treatment continue 12 month total 13 cycle . PROJECTED ACCRUAL : A total 14-30 patient accrue .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven myelodysplastic syndrome Less 30 % blast bone marrow PATIENT CHARACTERISTICS : Age : 18 Performance Status : Zubrod 02 Karnofsky 60100 % ECOG 02 Hematopoietic : Not specify Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : No New York Heart Association Class IV disease No antihypertensive medication within 24 hour amifostine administration Other : Not pregnant nursing Effective contraceptive method must use study No medical illness No psychosis Eligible patient HLA compatible donor refer bone marrow transplantation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy within 4 week study recover Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>Amifostine</keyword>
	<keyword>Ethyol</keyword>
	<keyword>Ethiofos</keyword>
	<keyword>Gammaphos</keyword>
</DOC>